. 2023 Apr 28;18(4):e0279326. doi: 10.1371/journal.pone.0279326

Table 4. Multivariable Cox proportional hazard model^* for the composite outcome among the post-propensity matched COVID-19 infected patients in the Banner Healthcare System between April 5, 2022, and August 1, 2022.

	Hazard Ratio (95% Confidence Interval)	Standard Error	P-value
Bebtelovimab monoclonal antibody use (yes vs. no)	0.75 (0.43–1.31)	0.21	0.31
Fully vaccinated status (Yes vs. no)	0.23 (0.12-.42)	0.07	<0.001
Age (≥65 vs. <65)	2.07 (1.15–3.74)	2.41	0.02
Immunocompromised^** (Yes vs. no)	4.60 (2.58–8.19)	5.19	<0.001

*Accounted for the paired data.

**Immunocompromised status (the patients with HIV/AIDS or solid organ transplants or malignancy including lymphoproliferative disorder).

Table 4. Multivariable Cox proportional hazard model* for the composite outcome among the post-propensity matched COVID-19 infected patients in the Banner Healthcare System between April 5, 2022, and August 1, 2022.